MNPR logo

Monopar Therapeutics Inc. Common Stock


MNPR: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.


Show MNPR Financials

Consumer Interest
SEC Filings

Recent trades of MNPR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by MNPR's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of MNPR in WallStreetBets Daily Discussion


Recent insights relating to MNPR

CNBC Recommendations

Recent picks made for MNPR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MNPR

Corporate Flights

Flights by private jets registered to MNPR